Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.

  title={Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.},
  author={Mohammad Reza Fallah and Keivan Khosravi and Mohammad Nasser Hashemian and Amir Hoshang Beheshtnezhad and Mohammad Taher Rajabi and Mohsen Gohari},
  journal={Current eye research},
  volume={35 1},
PURPOSE To evaluate clinical outcome(s) and complication(s) of topical bevacizumab (avastin) in patients with impending recurrent pterygium. PATIENTS AND METHODS This prospective clinical trial included 54 consecutive patients (54 eyes), who underwent pterygium surgery with bare sclera and mitomycin, and who were diagnosed with impending recurrent pterygium. Of the 54 patients, 26 received eye drops containing bevacizumab (5 mg/ml) twice a day and betamethasone four times daily for 1 week. In… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 33 extracted citations


Publications referenced by this paper.
Showing 1-10 of 37 references

Safety profile of topical VEGF neutralization at the cornea.

Investigative ophthalmology & visual science • 2009

Similar Papers

Loading similar papers…